Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

The conventional approach to cytotoxic T-lymphocyte (CTL) induction uses maximal antigen concentration with the intent of eliciting more CTL. However, the efficacy of this approach has not been systematically explored with regard to the quality of the CTLs elicited or their in vivo functionality. Here, we show that a diametrically opposite approach elicits CTLs that are much more effective at clearing virus. CTLs specific for a defined peptide epitope were selectively expanded with various concentrations of peptide antigen. CTLs generated with exceedingly low-dose peptide lysed targets sensitized with > 100-fold less peptide than CTLs generated with high-dose peptide. Differences in expression of T-cell antigen receptors or a number of other accessory molecules did not account for the functional differences. Further, high-avidity CTLs adoptively transferred into severe combined immunodeficient mice were 100- to 1000-fold more effective at viral clearance than the low-avidity CTLs, despite the fact that all CTL lines lysed virus-infected targets in vitro. Thus, the quality of CTLs is as important as the quantity of CTLs for adoptive immunotherapy, and the ability to kill virally infected targets in vitro is not predictive of in vivo efficacy, whereas the determinant density requirement described here is predictive. Application of these principles may be critical in developing effective adoptive cellular immunotherapy for viral infections and cancer.

[1]  L. Berg,et al.  In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides. , 1992, Journal of immunological methods.

[2]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[3]  S. Riddell,et al.  Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington , 1992 .

[4]  R. Zinkernagel,et al.  Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. , 1992, Journal of immunology.

[5]  J. Berzofsky,et al.  Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction. , 1993, Journal of immunology.

[6]  D. Jackson,et al.  Cytotoxic T cells recognize very early, minor changes in ectromelia virus-infected target cells. , 1976, The Australian journal of experimental biology and medical science.

[7]  J. Rothbard,et al.  Recruitment of alloreactive cytotoxic T lymphocytes by an antigenic peptide , 1989, European journal of immunology.

[8]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[9]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. DeLisi,et al.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Earl,et al.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses , 1991, Journal of virology.

[12]  M. Bevan,et al.  Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides , 1988, The Journal of experimental medicine.

[13]  B. Askonas,et al.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. , 1986, Immunology.

[14]  R. Zamoyska,et al.  Is CD8 dependence a true reflection of TCR affinity for antigen? , 1993, International immunology.

[15]  J. Bluestone,et al.  Identification of a monoclonal antibody specific for a murine T3 polypeptide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Yannelli The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. , 1991, Journal of immunological methods.

[17]  Wallace Gd,et al.  Reexamination of the efficacy of vaccination against mousepox. , 1985 .

[18]  J. Connolly,et al.  Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes , 1991, The Journal of experimental medicine.

[19]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[20]  P. Romero,et al.  The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules , 1992, The Journal of experimental medicine.

[21]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[22]  H. Clifford Lane,et al.  Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression , 1995, Nature Medicine.

[23]  J. Stewart Solid Phase Peptide Synthesis , 1984 .

[24]  M. Oldstone,et al.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo , 1984, Journal of virology.

[25]  J. Cerottini,et al.  Antigen recognition by H‐2‐restricted cytolytic T lymphocytes: inhibition of cytolysis by anti‐CDS monoclonal antibodies depends upon both concentration and primary sequence of peptide antigen , 1988, European journal of immunology.

[26]  D. Margulies,et al.  Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. , 1995, Journal of immunology.

[27]  R. Zinkernagel,et al.  Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled , 1977, The Journal of experimental medicine.